On May 27, 2015, James Gulley, M.D., Ph.D., and Ravi Madan, M.D., discussed some of the basic concepts of therapies that are designed to stimulate the immune system and treat patients with prostate cancer. They focused on immunotherapies that are FDA approved or in the late stages of clinical development for prostate cancer and discussed potential future roles of cancer immunotherapy, including data that suggest that immune therapies can be combined with other types of therapies. They also addressed when to use and not to use immunotherapy and provide data about what to expect clinically from this type of treatment. This 45-minute webinar was made possible by the generous support of Bavarian Nordic.
Cancer Research Institute's Breakthroughs in Cancer Immunotherapy Webinar Series are offered free to the public and feature informative updates from leaders in cancer immunotherapy, followed by a moderated Q&A. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.
